Lexicon Pharmaceuticals, Inc. LXRX
1.80
(0.06)
(3.23%)
as of 25 Sep
- Market cap
- $854.3M
- P/E
- 0.0×
Follow LXRX
Growth Flags
show if company had growth for consecutive years,
Insider Buys
alert about insiders buying in the last 12 month
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(45.92%) | (39.72%) | (16.01%) | (40.21%) | |
| (26.02%) | (20.83%) | (9.21%) | (25.70%) | ||
ROIC |
(68.83%) | (46.81%) | (18.49%) | (96.36%) | |
Return on Tangible Assets |
(66.72%) | (60.73%) | (14.67%) | (33.30%) | |
Average Days of Receivables |
12.02 | 17.47 | 61.73 | 14.46 | |
Free Cash Flow per Share |
(0.20) | (0.19) | (0.10) | (0.15) | |
Free Cash Flow |
(72.11) | (67.85) | (38.80) | (64.99) | |
Piotroski F-Score |
4.00 | 4.00 | 5.00 | 3.00 | |
| Other line items | |||||
Cash ROIC |
(24.64%) | (26.32%) | (9.17%) | (15.60%) | |
Accounts Receivable Turnover |
27.10 | 17.01 | 2.35 | 21.68 | |
Accounts Payable Turnover |
0.05 | 0.03 | 0.05 | 0.09 | |
Inventory Turnover |
1.06 | 1.07 | 1.48 | 0.52 | |
Average Days of Payables |
3,291.94 | 4,106.92 | 3,106.65 | 2,388.81 | |
Days of Inventory on Hand |
136.98 | 374.32 | 286.19 | 1,219.39 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
107.94% | 122.73% | 84.11% | 145.34% | |
Selling, General and Administrative Expense of Revenue |
85.82% | 74.93% | 50.18% | 85.23% | |
Share Based Compensation of Revenue |
15.83% | 25.13% | 18.02% | 30.61% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
1.05 | 1.35 | 1.49 | 1.06 | |
Depreciation/Fixed assets |
1.13 | 1.25 | 1.45 | 1.57 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Revenue per Share |
0.20 | 0.14 | 0.17 | 0.09 | |
Operating CF per Share |
(0.20) | (0.19) | (0.10) | (0.15) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Net Profit Margin |
(96.77%) | (101.08%) | (37.46%) | (147.38%) |
Columns are period end dates